$4.21 EPS Expected for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) This Quarter

Wall Street brokerages expect that Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) will report $4.21 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings. The lowest EPS estimate is $3.58 and the highest is $4.70. Jazz Pharmaceuticals reported earnings of $3.90 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 7.9%. The business is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full-year earnings of $17.05 per share for the current fiscal year, with EPS estimates ranging from $16.70 to $17.58. For the next financial year, analysts forecast that the company will report earnings of $18.14 per share, with EPS estimates ranging from $15.55 to $22.12. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The specialty pharmaceutical company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.13. The company had revenue of $813.72 million during the quarter, compared to analysts’ expectations of $853.73 million. Jazz Pharmaceuticals had a negative net margin of 13.63% and a positive return on equity of 22.45%. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.42 EPS.

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada cut their target price on shares of Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 2nd. The Goldman Sachs Group lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $202.00 to $196.00 in a research note on Wednesday, April 6th. Needham & Company LLC restated a “buy” rating and issued a $215.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, February 7th. Cowen upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a research note on Thursday, May 5th. Finally, Cowen upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a research note on Thursday, May 5th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $206.47.

Shares of Jazz Pharmaceuticals stock opened at $148.53 on Friday. The firm has a market cap of $9.26 billion, a PE ratio of -19.78, a price-to-earnings-growth ratio of 1.24 and a beta of 0.79. The firm’s 50-day simple moving average is $157.79 and its 200-day simple moving average is $143.27. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.06 and a current ratio of 3.39. Jazz Pharmaceuticals has a 1 year low of $117.64 and a 1 year high of $189.00.

In other Jazz Pharmaceuticals news, Director Anne Oriordan sold 466 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $148.95, for a total value of $69,410.70. Following the sale, the director now owns 9,245 shares in the company, valued at $1,377,042.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 10,772 shares of the firm’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $158.33, for a total transaction of $1,705,530.76. Following the completion of the sale, the chief executive officer now owns 346,062 shares in the company, valued at approximately $54,791,996.46. The disclosure for this sale can be found here. Insiders sold 22,330 shares of company stock worth $3,483,255 in the last 90 days. 4.30% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of JAZZ. Goldman Sachs Group Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 638.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,310,729 shares of the specialty pharmaceutical company’s stock valued at $166,987,000 after acquiring an additional 1,133,121 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $97,566,000. Farallon Capital Management LLC bought a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $74,859,000. Norges Bank bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $71,557,000. Finally, Deep Track Capital LP bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $63,700,000. Institutional investors and hedge funds own 93.23% of the company’s stock.

About Jazz Pharmaceuticals (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

See Also